{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T13:40:59Z","timestamp":1770730859091,"version":"3.49.0"},"reference-count":175,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.medcli.2024.10.018","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T12:23:51Z","timestamp":1736511831000},"page":"305-305.e17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Gu\u00eda para el diagn\u00f3stico y el tratamiento de la leucemia linfoc\u00edtica cr\u00f3nica y el linfoma linfoc\u00edtico de c\u00e9lulas peque\u00f1as del Grupo Espa\u00f1ol de Leucemia Linfoc\u00edtica Cr\u00f3nica (GELLC)"],"prefix":"10.1016","volume":"164","author":[{"given":"\u00c1ngeles","family":"Medina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Munta\u00f1ola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-\u00c1ngel","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pau","family":"Abrisqueta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Alcoceba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"de la Serna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Espinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Loscertales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Terol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucrecia","family":"Y\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesc","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2024.10.018_bib0880","doi-asserted-by":"crossref","first-page":"1046307","DOI":"10.3389\/fonc.2022.1046307","article-title":"Incidence and survival of lymphoid neoplasms in Spain, 2002-2013: A population-based study from the Spanish Network of Cancer Registries (REDECAN)","volume":"12","author":"Pla","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib0885","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib0890","unstructured":"Oxford Centre for Evidence-Based Medicine: Levels of Evidence. 2009 [consultado 14 Ago 2024]. Disponible en: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009"},{"key":"10.1016\/j.medcli.2024.10.018_bib0895","unstructured":"NCCN development and Update of Guidelines. NCCN. 2024 [consultado 14 Ago 2024]. Disponible en: https:\/\/www.nccn.org\/guidelines\/guidelines-process\/development-and-update-of-guidelines"},{"key":"10.1016\/j.medcli.2024.10.018_bib0900","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/cyto.b.21595","article-title":"Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project","volume":"94","author":"Rawstron","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.medcli.2024.10.018_bib0905","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1046\/j.1365-2141.2002.03719.x","article-title":"CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B-cell chronic lymphocytic leukaemia cells","volume":"118","author":"Buhmann","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib0910","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib0915","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2024.10.018_bib0920","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib0925","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.medcli.2024.10.018_bib0930","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2019003453","article-title":"International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia","volume":"135","author":"Condoluci","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib0935","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/blood-2005-12-051458","article-title":"Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia","volume":"109","author":"Wierda","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib0940","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","article-title":"Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia","volume":"124","author":"Pflug","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib0945","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2024.10.018_bib0950","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1182\/blood-2016-07-724740","article-title":"The CLL-IPI applied in a population-based cohort","volume":"128","author":"Da Cunha-Bang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib0955","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2017-03-772285","article-title":"In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI","volume":"129","author":"Rigolin","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib0960","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood-2017-09-806034","article-title":"Chronic lymphocytic leukemia international prognostic index: A systematic review and meta-analysis","volume":"131","author":"Molica","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib0965","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1080\/10428194.2016.1257791","article-title":"Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): A comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI)","volume":"58","author":"Molica","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.medcli.2024.10.018_bib0970","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1002\/ajh.24960","article-title":"Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases","volume":"93","author":"Gentile","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib0975","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.24660","article-title":"Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI","volume":"92","author":"Delgado","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib0980","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00277-018-3350-5","article-title":"Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: A systematic review and meta-analysis","volume":"97","author":"Molica","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib0985","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood.2023022564","article-title":"Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies","volume":"143","author":"Langerbeins","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib0990","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.10.018_bib0995","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","article-title":"Cytogenetic complexity in chronic lymphocytic leukemia: Definitions, associations, and clinical impact","volume":"133","author":"Baliakas","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1000","doi-asserted-by":"crossref","first-page":"e707","DOI":"10.1097\/HS9.0000000000000707","article-title":"Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations","volume":"6","author":"Baliakas","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.medcli.2024.10.018_bib1005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41375-022-01802-y","article-title":"Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: A study by ERIC in HARMONY","volume":"37","author":"Mansouri","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2024.10.018_bib1010","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/s41375-024-02267-x","article-title":"ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update","volume":"38","author":"Malcikova","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2024.10.018_bib1015","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1020","unstructured":"Recomendaciones sobre el estudio de secuenciaci\u00f3n masiva en Neoplasias Hematol\u00f3gicas. Documento de Consenso del Grupo Espa\u00f1ol de Biologia Molecular en Hematologia. 2023."},{"key":"10.1016\/j.medcli.2024.10.018_bib1025","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia","volume":"3","author":"Woyach","year":"2017","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2024.10.018_bib1030","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","article-title":"BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib","volume":"7","author":"Bonfiglio","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.medcli.2024.10.018_bib1035","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood-2023-180143","article-title":"Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN Study","volume":"142","author":"Brown","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1040","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.medcli.2024.10.018_bib1045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood.2021010845","article-title":"The CLL12 trial: Ibrutinib vs placebo in treatment-na\u00efve, early-stage chronic lymphocytic leukemia","volume":"139","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1050","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.23.00933","article-title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update","volume":"41","author":"Dale","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1055","doi-asserted-by":"crossref","first-page":"101401","DOI":"10.1016\/j.jgo.2022.10.016","article-title":"Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study","volume":"14","author":"De la Rubia","year":"2023","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1060","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: First-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.medcli.2024.10.018_bib1065","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood-2021-153146","article-title":"Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy","volume":"138","author":"Woyach","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1070","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: Final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2024.10.018_bib1075","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1080","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2023-174750","article-title":"Acalabrutinib \u00b1 Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN","volume":"142","author":"Sharman","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1085","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/hon.3163_154","article-title":"Zanubrutinib versus bendamustine + rituximab in patients with treatment-na\u00efve CLL\/SLL: Extended follow-up of the Sequoia study","volume":"41","author":"Shadman","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1090","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.10.018_bib1095","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.10.018_bib1100","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1105","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1110","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.10.018_bib1115","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024024667","article-title":"Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R\/R CLL\/SLL: Final Comparative Analysis of ALPINE","author":"Brown","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1120","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1182\/bloodadvances.2023009739","article-title":"Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia","volume":"7","author":"Roeker","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.medcli.2024.10.018_bib1125","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1130","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1135","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1140","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2023-177713","article-title":"First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study","volume":"142","author":"Moreno","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1145","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood-2023-187128","volume":"142","author":"Ghia","year":"2023","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2024.10.018_bib1150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/blood-2023-182397","article-title":"Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study","volume":"142","author":"Itsara","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1155","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/bjh.17984","article-title":"Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: Apooled analysis from four clinical trials","volume":"196","author":"Allan","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1160","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: Primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1165","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2024.10.018_bib1170","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1175","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1180","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: Updated results of the CLL11 study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2024.10.018_bib1185","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/17474086.2022.2067526","article-title":"Cardiotoxicity of BTK inhibitors: Ibrutinib and beyond","volume":"15","author":"Christensen","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1190","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000528019","article-title":"Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias\/Sudden Cardiac Death","volume":"68","author":"Boriani","year":"2023","journal-title":"Chemotherapy"},{"key":"10.1016\/j.medcli.2024.10.018_bib1195","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2022016953","article-title":"Ventricular arrhythmias and sudden death events following acalabrutinib initiation","volume":"140","author":"Bhat","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1200","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3324\/haematol.2021.278901","article-title":"Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: Pooled analysis of 762 patients","volume":"107","author":"Brown","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2024.10.018_bib1205","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.10.018_bib1210","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.10.018_bib1215","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1220","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: Phase III Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1225","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib Versus Investigator's Choice in Relapsed\/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results","volume":"6","author":"Ghia","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.medcli.2024.10.018_bib1230","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.10.018_bib1235","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1240","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/hon.3163_156","article-title":"MURANO: Final 7 year follow up and retreatment analysis in venetoclax-rituximab (VenR)-treated patients with relapsed\/refractory chronic lymphocytic leukemia (R\/R CLL)","volume":"41","author":"Kater","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1245","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/bloodadvances.2022007812","article-title":"Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.medcli.2024.10.018_bib1250","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-137415","article-title":"Efficacy of Subsequent Novel Targeted Therapies. Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed\/Refractory Chronic Lymphocytic Leukemia (R\/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study","volume":"136","author":"Harrup","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1255","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.2020004782","article-title":"BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax","volume":"135","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1260","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: A real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1265","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: A real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2024.10.018_bib1270","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.medcli.2024.10.018_bib1275","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2024.10.018_bib1280","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: A phase 2, open-label, single-arm study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1285","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: An interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1290","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: Results from a multicenter study of 683 patients","volume":"28","author":"Mato","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1295","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1158\/1078-0432.CCR-19-0361","article-title":"Tumor Lysis Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice","volume":"25","author":"Roeker","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.medcli.2024.10.018_bib1300","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/bjh.16271","article-title":"The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia","volume":"188","author":"Eyre","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1305","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.hoc.2021.03.008","article-title":"Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors","volume":"35","author":"Thompson","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.medcli.2024.10.018_bib1310","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/bloodadvances.2020002454","article-title":"Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib","volume":"4","author":"Hampel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.medcli.2024.10.018_bib1315","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1111\/bjh.16948","article-title":"Pseudo-Richter transformation of chronic lymphocytic leukaemia\/small lymphocytic lymphoma following ibrutinib interruption: A diagnostic pitfall","volume":"191","author":"Barnea Slonim","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1320","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hon.2933","article-title":"The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma","volume":"39","author":"Wang","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1325","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/CCO.0000000000000897","article-title":"Beyond ibrutinib: Novel BTK inhibitors for the treatment of chronic lymphocytic leukemia","volume":"34","author":"Perutelli","year":"2022","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1330","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1335","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2023-185852","article-title":"Pirtobrutinib in Post-cBTKi CLL\/SLL: \u223c30 Months Follow-up and Subgroup Analysis With\/Without Prior BCL2i from the Phase 1\/2 BRUIN Study","volume":"142","author":"Woyach","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1340","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2024.10.018_bib1345","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.10.018_bib1350","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","article-title":"Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy","volume":"26","author":"Mato","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.medcli.2024.10.018_bib1355","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood.2020008502","article-title":"treat chronic lymphocytic leukemia after venetoclax","volume":"138","author":"Lew","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1360","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s11912-023-01454-w","article-title":"Bohn J-P. Next-Generation Sequencing-Optimal Sequencing of Therapies in Relapsed\/Refractory Chronic Lymphocytic Leukemia (CLL)","volume":"25","author":"Simon","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.medcli.2024.10.018_bib1365","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41409-023-01955-z","article-title":"The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: A perspective from the Chronic Malignancies Working Party of the EBMT","volume":"58","author":"Tournilhac","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.medcli.2024.10.018_bib1370","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): A multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2024.10.018_bib1375","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1182\/blood-2023-179529","article-title":"Lisocabtagene Maraleucel (liso-cel) in R\/R CLL\/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004","volume":"142","author":"Siddiqi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1380","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib Plus Venetoclax in Relapsed\/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1385","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.18357","article-title":"Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia","volume":"199","author":"Hampel","year":"2022","journal-title":"Br J Haematol"},{"issue":"Suppl 2","key":"10.1016\/j.medcli.2024.10.018_bib1390","first-page":"S19","article-title":"Approach to a patient with \u00abdouble refractory\u00bb chronic lymphocytic leukemia: \u00abDouble, double toil and trouble\u00bb (Shakespeare)","volume":"97","author":"Aronson","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1395","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.23785","article-title":"Autoimmune cytopenias in chronic lymphocytic leukemia","volume":"89","author":"Visco","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1400","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3324\/haematol.2010.036152","article-title":"Chronic lymphocytic leukemia and autoimmunity: A systematic review","volume":"96","author":"Hodgson","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2024.10.018_bib1405","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/blood.2019003809","article-title":"How I treat cold agglutinin disease","volume":"137","author":"Berentsen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1410","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1182\/blood.2019003808","article-title":"How I treatwarm autoimmune hemolytic anemia","volume":"137","author":"Barcellini","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1415","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood.2019003686","article-title":"How I manage autoimmune cytopenias in patients with lymphoid cancer","volume":"139","author":"Porpaczy","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1420","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/blood.2019003809","article-title":"How I treat cold agglutinin disease","volume":"137","author":"Berentsen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1425","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3390\/jcm10102064","article-title":"The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia","volume":"10","author":"Noto","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.medcli.2024.10.018_bib1430","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1182\/blood-2022-168369","article-title":"The Use of Novel Therapies Reduces the Risk of Autoimmune Complications in CLL: A Population-Based Study in British Columbia","volume":"140","author":"Ramadan","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1435","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2024.10.018_bib1440","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.23785","article-title":"Autoimmune cytopenias in chronic lymphocytic leukemia","volume":"89","author":"Visco","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1445","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/17474086.2018.1489720","article-title":"Autoimmune cytopenias in chronic lymphocytic leukemia: A concise review and treatment recommendations","volume":"11","author":"De Back","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1450","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/ejh.13858","article-title":"Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma","volume":"109","author":"Daniel","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1455","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1460","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1465","first-page":"1267","article-title":"Detection of Richter's transformation of chronic lymphocytic leukemia by PET\/CT","volume":"47","author":"Bruzzi","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.medcli.2024.10.018_bib1470","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","article-title":"Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia","volume":"123","author":"Falchi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1475","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/leu.2015.21","article-title":"Diagnostic and prognostic role of PET\/CT in patients with chronic lymphocytic leukemia and progressive disease","volume":"29","author":"Mauro","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2024.10.018_bib1480","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1485","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: Experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2024.10.018_bib1490","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjh.16748","volume":"190","author":"Abrisqueta","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1495","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","volume":"35","author":"Al-Sawaf","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2024.10.018_bib1500","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00277-021-04603-y","article-title":"Outcomes of Richter's transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): An analysis of the SEER database","volume":"100","author":"Elnair","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1505","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1510","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14177","article-title":"NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome","volume":"175","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1515","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am J Hematol."},{"key":"10.1016\/j.medcli.2024.10.018_bib1520","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.15035","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1525","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/10428190109064589","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome","volume":"42","author":"Dabaja","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.medcli.2024.10.018_bib1530","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.11238","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.medcli.2024.10.018_bib1535","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2007.11.8513","article-title":"Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"26","author":"Tsimberidou","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1540","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clml.2013.03.012","article-title":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome","volume":"13","author":"Tsimberidou","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.medcli.2024.10.018_bib1545","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ejh.12474","article-title":"Platinum and high-dose cytarabine-based regimens are efficient in ultra high\/high-risk chronic lymphocytic leukemia and Richter's syndrome: Results of a French retrospective multicenter study","volume":"95","author":"Durot","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1550","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2021004865","article-title":"Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.medcli.2024.10.018_bib1555","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","volume":"30","author":"Cwynarski","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1560","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.clml.2017.10.002","article-title":"Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience","volume":"18","author":"Kharfan-Dabaja","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.medcli.2024.10.018_bib1565","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.bbmt.2016.06.025","article-title":"Hematopoietic Cell Transplantation for Richter Syndrome","volume":"22","author":"El-Asmar","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.medcli.2024.10.018_bib1570","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1575","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1580","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-138904","article-title":"Safety and Efficacy of CD19-CAR T Cells in Richter's Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia","volume":"136","author":"Benjamini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1585","doi-asserted-by":"crossref","first-page":"828471","DOI":"10.3389\/fonc.2022.828471","article-title":"Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation","volume":"12","author":"Ortiz-Maldonado","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1590","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/bloodadvances.2020002783","article-title":"Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome","volume":"4","author":"Kittai","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.medcli.2024.10.018_bib1595","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1016\/S2352-3026(21)00305-7","article-title":"Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): Analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study","volume":"8","author":"Eyre","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1600","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ccr3.269","article-title":"Ibrutinib and rituximab induced rapid response in refractory Richter syndrome","volume":"3","author":"Lamar","year":"2015","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.medcli.2024.10.018_bib1605","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood-2014-12-617522","article-title":"Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: A phase 1b\/2 study","volume":"126","author":"Jaglowski","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1610","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/s12885-019-5717-y","volume":"19","author":"Appleby","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.medcli.2024.10.018_bib1615","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood.2021011386","article-title":"Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome","volume":"139","author":"Davids","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1620","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bjh.15514","article-title":"PD-1 is highly expressed by neoplastic B-cells in Richter transformation","volume":"185","author":"Behdad","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1625","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.16762","article-title":"Pembrolizumab in relapsed or refractory Richter syndrome","volume":"190","author":"Armand","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1630","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.15508","article-title":"Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: Experience at a single academic centre","volume":"185","author":"Rogers","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1635","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/bloodadvances.2022008790","article-title":"A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL","volume":"7","author":"Jain","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.medcli.2024.10.018_bib1640","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: A phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1645","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1182\/blood-2021-147467","article-title":"Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group","volume":"138","author":"Guieze","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1650","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1655","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1660","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood-2022-158298","article-title":"Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b\/2 Trial (EPCORE CLL-1)","volume":"140","author":"Kater","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1665","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1670","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.blre.2018.03.004","article-title":"Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections","volume":"32","author":"Hilal","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.medcli.2024.10.018_bib1675","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/bjh.15918","article-title":"Chronic lymphocytic leukaemia: The role of T cells in a B cell disease","volume":"186","author":"Man","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1680","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: A multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1685","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","article-title":"COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: A joint study by ERIC, the European Research Initiative on CLL, and CLL Campus","volume":"34","author":"Scarf\u00f2","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2024.10.018_bib1690","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40164-020-00195-x","article-title":"Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country","volume":"9","author":"Munta\u00f1ola","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1695","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood.2021011841","article-title":"COVID-19 in patients with CLL: Improved survival outcomes and update on management strategies","volume":"138","author":"Roeker","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1700","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.2022016147","article-title":"Patients with CLL have a lower risk of death from COVID-19 in the Omicron era","volume":"140","author":"Niemann","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2024.10.018_bib1705","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/10428194.2023.2280886","article-title":"The mortality of COVID-19 in CML patients from 2020 until 2022: Results from the EPICOVIDEHA survey","volume":"65","author":"El-Ashwah","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.medcli.2024.10.018_bib1710","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/bloodadvances.2021006101","article-title":"Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies","volume":"6","author":"Jim\u00e9nez","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.medcli.2024.10.018_bib1715","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/ajh.26951","article-title":"Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms","volume":"98","author":"Jim\u00e9nez","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1720","doi-asserted-by":"crossref","first-page":"170","DOI":"10.14740\/jh1140","article-title":"Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia","volume":"12","author":"Andersson","year":"2023","journal-title":"J Hematol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1725","doi-asserted-by":"crossref","first-page":"2387221","DOI":"10.1080\/21645515.2024.2387221","article-title":"Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France","volume":"20","author":"Loubet","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.medcli.2024.10.018_bib1730","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2024.10.018_bib1735","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2024.10.018_bib1740","article-title":"Evidence for the Efficacy of COVID-19 Convalescent Plasma","author":"Klassen","year":"2024","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.medcli.2024.10.018_bib1745","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2414957121","article-title":"Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma","volume":"121","author":"Dragotakes","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.medcli.2024.10.018_bib1750","doi-asserted-by":"crossref","first-page":"100403","DOI":"10.1016\/j.esmoop.2022.100403","article-title":"Managing hematological cancer patients during the COVID-19 pandemic: An ESMO-EHA Interdisciplinary Expert Consensus","volume":"7","author":"Buske","year":"2022","journal-title":"ESMO Open"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775324006961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775324006961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T19:27:43Z","timestamp":1742671663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775324006961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":175,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0025775324006961"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2024.10.018","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gu\u00eda para el diagn\u00f3stico y el tratamiento de la leucemia linfoc\u00edtica cr\u00f3nica y el linfoma linfoc\u00edtico de c\u00e9lulas peque\u00f1as del Grupo Espa\u00f1ol de Leucemia Linfoc\u00edtica Cr\u00f3nica (GELLC)","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2024.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}